AGN

COP28 must deliver for the most vulnerable, President-Designate tells UN climate change conference

Retrieved on: 
Sunday, June 11, 2023
SIDS, Food, COP28, Solidarity, Global stocktake, 2019 UN Climate Action Summit, G77, Negotiation, AGN, Human, LDC, Carbon, Paris Agreement, Wind, COP, Biodiversity, Indigenous peoples, Least developed countries, Expo 2020, Climate change, Capacity building, Fossil, Nature, African Group, COP27, Party, Global North and Global South, Growth, Health, Delegation, Environment, Kunst- und Ausstellungshalle der Bundesrepublik Deutschland, Conference, SB, Tourism, Agriculture, Renewable energy, UNFCCC

And we will give the space and enabling environment to discuss, debate and align on every mandate across every climate pillar."

Key Points: 
  • And we will give the space and enabling environment to discuss, debate and align on every mandate across every climate pillar."
  • "Everyone is affected and the most vulnerable communities who have done the least to cause climate change, are the most affected.
  • He introduced COP28's Youth Climate Champion, Shamma Al Mazrui, who stressed the importance of including youth in all conversations around climate change.
  • As mandated by the Paris Climate Agreement, COP28 UAE will deliver the first ever Global Stocktake – a comprehensive evaluation of progress against climate goals.

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Retrieved on: 
Tuesday, June 6, 2023
ACC, CSE, Idiopathic pulmonary fibrosis, AGN, NMDA, Doctor of Philosophy, Cough, Patient, IPF, Conference, Pharmaceutical industry, Research

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.

Key Points: 
  • VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.
  • The ACC is the world's leading educational meeting for healthcare professionals involved in the research and management of patients with cough.
  • Christopher Bryan, PhD, Vice President of Research and Operations at Algernon Pharmaceuticals, will present “An update on NP-120 (ifenprodil): A subunit-selective NMDA receptor antagonist for the treatment of cough” during a thematic oral session on antitussive drug development programs.
  • The focus of the talk will be on data from AGN-120-1, the Company’s Phase 2a clinical trial in Idiopathic Pulmonary Fibrosis (IPF) and associated cough.

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Retrieved on: 
Monday, June 5, 2023
Molecule, Neuron, DMT, CSE, DMT: The Spirit Molecule, Stroke, Penile spines, AGN, Pharmacokinetics, Dendrite, Brain, Research, TBI, Trial of the century, Plasma, Dendritic spine, Traumatic brain injury, Synapse, BDNF, Safety, Pharmaceutical industry

AGN Neuro is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (TBI).

Key Points: 
  • AGN Neuro is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (TBI).
  • AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration.
  • AGN Neuro has now established a single dose regimen which can now be used in its first Phase 2 study for stroke and TBI.
  • “Now that we have established the safety of a single sub psychedelic dose of DMT, we are planning to accelerate our DMT Phase 2 studies accordingly, for both stroke and TBI.”

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Retrieved on: 
Wednesday, May 31, 2023
Telmisartan, Patent, Asthma, CSE, Heart failure, AGN, Medicine, JPO, Fibrosis, Algernon, Diabetic nephropathy, CKD, Kidney disease, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.

Key Points: 
  • The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.
  • The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney disease.
  • “This is the first allowance notice received from the JPO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • “What is also noteworthy, is that Repirinast was originally developed and approved in the Japanese market for the treatment of asthma and so this notice of allowance is even more meaningful.”

Algernon Pharmaceuticals Announces Closing of Rights Offering

Retrieved on: 
Friday, May 5, 2023
Acceleration, Exercise, Unit, Minority, CSE, MI, Canadian Securities Exchange, Dealer, Share (finance), RCC, AGN, Rights, Warrant, Knowledge, Multilateral, Security (finance)

VANCOUVER, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “Rights Offering”).

Key Points: 
  • VANCOUVER, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “Rights Offering”).
  • The total number of issued and outstanding Shares of the Company upon completion of the Rights Offering will be 14,550,757, before the exercise of the Warrants.
  • To the knowledge of the Company, after reasonable inquiry, no person became a new shareholder holding more than 10% of the Shares upon closing of the Rights Offering.
  • The proceeds of the Rights Offering are expected to be used for working capital and general corporate purposes and administrative expenses.

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Retrieved on: 
Monday, April 17, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, Heart failure, NASH, United States Patent and Trademark Office, AGN, Medicine, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, Diabetic nephropathy, CKD, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.

Key Points: 
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms.
  • “This is the first allowance notice received from the USPTO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Retrieved on: 
Tuesday, April 4, 2023
DMT, CSE, Stroke, AGN, Pharmacokinetics, Brain, TBI, Trial of the century, Patient, Traumatic brain injury, Safety, Pharmaceutical industry

AGN Neuro also reports that the safety review committee has approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues.

Key Points: 
  • AGN Neuro also reports that the safety review committee has approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues.
  • Once the correct dose has been established in the first part of the study, the second part of the study will include dosing subjects for 6 hours with repeated dosing over a two-week period.
  • The Company is working with its top stroke and traumatic brain injury (TBI) experts to design Phase 2 studies for the continued investigation of DMT.
  • “This is another important step in our DMT clinical research program,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Retrieved on: 
Monday, April 3, 2023
DMT, CSE, Reg, Stroke, AGN, Research, TBI, USD, Traumatic brain injury, Brain, REG WindPower, Pharmaceutical industry

Under the Reg A+, AGN Neuro will be offering up to 37.5% of its common shares, with majority ownership residing with AGN Pharma.

Key Points: 
  • Under the Reg A+, AGN Neuro will be offering up to 37.5% of its common shares, with majority ownership residing with AGN Pharma.
  • The class A common shares will be offered at USD $1 per share with a minimum investment of USD $1,000 required.
  • Bonus shares will be issued on the following basis:
    AGN Pharma has valued AGN Neuro’s psychedelic DMT stroke and traumatic brain injury (TBI) research program at USD $20M.
  • “We look forward to starting AGN Neuro’s online digital marketing campaign for investors soon,” said Christopher J. Moreau, CEO of AGN Pharma.

Algernon Pharmaceuticals Announces Launch of Rights Offering

Retrieved on: 
Tuesday, March 21, 2023
Acceleration, Exercise, CSE, Canadian Securities Exchange, Date, RCC, Share (finance), AGN, Eligibility, Sale, Circular, Expiry Date (miniseries), Notice, SEDAR, DRS, Expiration date, News, Regulation, Security (finance), Pacific Ocean, Rights, Unit, Warrant

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).

Key Points: 
  • VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).
  • Pricing of the Rights Offering is mandated by applicable Canadian securities law and the policies of the CSE which require the Company to offer existing Shareholders a significant discount to purchase new securities in order to provide a meaningful incentive to Shareholders to participate in the Rights Offering.
  • Upon completion of the Rights Offering and assuming all Rights are exercised, the Company will have 19,333,976 Shares outstanding, of which the Shares issued under the Rights Offering represent 50%, assuming no Warrants issued pursuant to the Rights Offering are exercised.
  • The proceeds of the Rights Offering are expected to be used for working capital and general corporate purposes and administrative expenses.

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Retrieved on: 
Thursday, March 2, 2023
National Institute of Neurological Disorders and Stroke, Doctor of Philosophy, University of Oxford, NFL, Oxford University Press, Biomedical sciences, Research, Journal of Neurotrauma, Journal, Science, Patient, Editorial board, Algernon, A Practical Guide to a Spectacular Suicide, MD, Norman, George Washington University School of Medicine & Health Sciences, Diagnosis, DMT, N,N-Dimethyltryptamine, AFL, Washington University in St. Louis, Washington University School of Medicine, Neurology, NINDS, Traumatic brain injury, DSM-IV codes, TBI, National Football League, CSE, AGN, Medical device, Stroke

Dr. Brody, MD, PhD is a board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases.

Key Points: 
  • Dr. Brody, MD, PhD is a board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases.
  • Dr. Brody was the Norman J. Stupp Professor of Neurology at the Washington University School of Medicine in St. Louis.
  • Dr. Brody was also the Washington University site director for the National Football League (NFL) Neurological player care program.
  • Dr. Brody is the editor in chief of the Journal of Neurotrauma and a member of the Editorial Board of Acta Neuropathologica.